Odyssey Therapeutics, Inc. (ODTX) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$23.35

From 52W high−15.23%

Volume2.60M

Market cap$1.17B

P/E (TTM)—

P/S (TTM)393.7x

Div yield—

Key dataSep 18, 2026

Open

$23.35

From 52W high

−15.23%

Volume

2.60M

Market cap

$1.17B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.1x

P/E (TTM)

—

RSI (14)

53.2

MomentumView details →

1D Return

+5.00%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−6.1x

EV/Sales

297.7x

P/S (TTM)

393.7x

P/B (TTM)

2.8x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−4994.86%

EBITDA Margin

−4860.42%

ROE (TTM)

−35.29%

ROA (TTM)

−30.72%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+5.00%

YTD Return

—

1Y Return

—

RSI (14)

53.2

vs 50D SMA

+13.01%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.06x

Current Ratio

11.36x

Quick Ratio

11.36x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$6.77

EPS Surprise

−508.00%

Beats (12Q)

0/12

Next Q EPS Est

−$1.08

Avg Surprise (4Q)

−508.00%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsNov 4, 2026 →

Latest newsMore news →

Evotec SE announced a strategic R&D collaboration with Odyssey Therapeutics to discover new treatments for autoimmune and inflammatory diseases using Evotec's AI-enabled discovery platform.45d ago

Odyssey Therapeutics reported a GAAP net loss of $52.8 million for Q2 2026, compared to a net loss of $41.2 million in Q2 2025, with cash and marketable securities of $433.1 million as of June 30, 2026.48d ago

Similar companies

Alto Neuroscience, Inc.ANRO MannKind CorporationMNKD Apnimed, Inc.APMD Aktis Oncology, Inc.AKTS Replimune Group, Inc.REPL Savara Inc.SVRA Find similar companies →

Latest newsMore news →

Evotec SE announced a strategic R&D collaboration with Odyssey Therapeutics to discover new treatments for autoimmune and inflammatory diseases using Evotec's AI-enabled discovery platform.45d ago Odyssey Therapeutics reported a GAAP net loss of $52.8 million for Q2 2026, compared to a net loss of $41.2 million in Q2 2025, with cash and marketable securities of $433.1 million as of June 30, 2026.48d ago